Case Presentation

Convalescent plasma therapy in aHUS patient with SARS-CoV-2 infection

Emma Diletta Stea*, Virginia Pronzo, Francesco Pesce, Marco Fiorentino, Adele Mitrotti, Vincenzo Di Leo, Cosma Cortese, Annalisa Casanova, Sebastiano Nestola, Flavia Capaccio and Loreto Gesualdo

Published: 22 April, 2022 | Volume 6 - Issue 1 | Pages: 036-039

Endotheliosis, thrombotic microangiopathy and complement system over activation have been described as pathologic features of tissue damage in the setting of coronavirus disease. Interestingly, complement-mediated cell injury is also a typical feature of atypical Hemolytic Uremic Syndrome. Indeed, a growing body of literature has described a higher risk of microangiopathy recurrence, in aHUS patients who test positive for SARS-CoV-2. The correct clinical and therapeutic management patients with a history of HUS and SARS-CoV-2 infection is not well established.
We report a case of SARS-CoV-2 infection in an aHUS patient who did not develop a recurrence of the disease and that was successfully treated with convalescent immune plasma therapy.

Read Full Article HTML DOI: 10.29328/journal.jcn.1001088 Cite this Article Read Full Article PDF


aHUS; Complement; Sars-CoV-2; Plasma


  1. Noris M, Benigni A, Remuzzi G. The case of complement activation in COVID-19 multiorgan impact. Kidney Int. 2020; 98: 314-322. PubMed: https://pubmed.ncbi.nlm.nih.gov/32461141/
  2. Zipfel PF, Wiech T, Stea ED, Skerka C. CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. J Am Soc Nephrol. 2020; 31: 241-256. PubMed: https://pubmed.ncbi.nlm.nih.gov/31980588/
  3. Petrungaro A, Quartarone E, Sciarrone P. Anti-SARS-CoV-2 hyperimmune plasma workflow. Transfus Apher Sci. 2020; 59: 102850. PubMed: https://pubmed.ncbi.nlm.nih.gov/32540345/
  4. Cusi MG, Conticini E, Gandolfo C, Anichini G, Savellini GG, et al. Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience. BMC Infect Dis. 2021; 21: 630. PubMed: https://pubmed.ncbi.nlm.nih.gov/34210259/
  5. Ville S, Le Bot S, Chapelet-Debout A, Blancho G, Fremeaux-Bacchi V, et al. Atypical HUS relapse triggered by COVID-19. Kidney Int. 2021; 99: 267-268. PubMed: https://pubmed.ncbi.nlm.nih.gov/33188793/
  6. Yu J, Yuan X, Chen H, Chaturvedi S, Braunstein EM, et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. 2020; 136: 2080-2089. PubMed: https://pubmed.ncbi.nlm.nih.gov/32877502/
  7. Maharaj N, Sankat S, Spann J, Goorachan S, Sookoo A. POS-041 Haemolytic Uremic Syndrome (HUS) with Covid-19 infection: 2 case reports. Is there a direct link? Kidney Int Rep. 2021; 6: S18–19. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049736/
  8. Jhaveri KD, Meir LR, Flores Chang BS, Parikh R, Wanchoo R, et al. Thrombotic microangiopathy in a patient with COVID-19. Kidney Int. 2020; 98: 509-512. PubMed: https://pubmed.ncbi.nlm.nih.gov/32525010/
  9. Trimarchi H, Gianserra R, Lampo M, Monkowski M, Lodolo J. Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome. Clin Kidney J. 2020; 13: 739-741. PubMed: https://pubmed.ncbi.nlm.nih.gov/33117528/


Figure 1

Figure 1

Figure 1

Figure 2

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?